1. World Health Organization (WHO). (2022). Leishmaniasis. Fact Sheets. 〈https://www.who.int/news-room/fact-sheets/detail/leishmaniasis〉 Accessed 06 Dez 2022.
2. Brasil Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. (2017). Manual de vigilância da leishmaniose tegumentar [recurso eletrônico] (2 ed.). 〈http://bvsms.saude.gov.br/bvs/publicacoes/manual_vigilancia_leishmaniose_〉 Accessed 03 Dez 2022.
3. Pharmacological aspects of drug therapy used for cutaneous leishmaniasis: a literature review;Comandolli-Wyrepkowski;Electron. J. Collec. Health,2020
4. Genotoxic effects of the antileishmanial drug glucantime®;Lima;Arch. Toxicol.,2010
5. Increasing failure of miltefosine in the treatment of kala-azar in nepal and the potential role of parasite drug resistance, reinfection, or noncompliance;Rijal;Clin. Infect. Dis.,2013